RU2735277C2 - 3,3-дифторпиперидинкарбаматные гетероциклические соединения в качестве антагонистов nr2b nmda-рецептора - Google Patents

3,3-дифторпиперидинкарбаматные гетероциклические соединения в качестве антагонистов nr2b nmda-рецептора Download PDF

Info

Publication number
RU2735277C2
RU2735277C2 RU2017142005A RU2017142005A RU2735277C2 RU 2735277 C2 RU2735277 C2 RU 2735277C2 RU 2017142005 A RU2017142005 A RU 2017142005A RU 2017142005 A RU2017142005 A RU 2017142005A RU 2735277 C2 RU2735277 C2 RU 2735277C2
Authority
RU
Russia
Prior art keywords
compound
mmol
test
nr2b
methyl
Prior art date
Application number
RU2017142005A
Other languages
English (en)
Russian (ru)
Other versions
RU2017142005A3 (enExample
RU2017142005A (ru
Inventor
Гидеон Шапиро
Original Assignee
Руджен Холдингс (Кайман) Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Руджен Холдингс (Кайман) Лимитед filed Critical Руджен Холдингс (Кайман) Лимитед
Publication of RU2017142005A publication Critical patent/RU2017142005A/ru
Publication of RU2017142005A3 publication Critical patent/RU2017142005A3/ru
Application granted granted Critical
Publication of RU2735277C2 publication Critical patent/RU2735277C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RU2017142005A 2015-06-01 2016-05-31 3,3-дифторпиперидинкарбаматные гетероциклические соединения в качестве антагонистов nr2b nmda-рецептора RU2735277C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562169107P 2015-06-01 2015-06-01
US62/169,107 2015-06-01
PCT/US2016/035098 WO2016196513A1 (en) 2015-06-01 2016-05-31 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists

Publications (3)

Publication Number Publication Date
RU2017142005A RU2017142005A (ru) 2019-07-09
RU2017142005A3 RU2017142005A3 (enExample) 2019-11-19
RU2735277C2 true RU2735277C2 (ru) 2020-10-29

Family

ID=57441824

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017142005A RU2735277C2 (ru) 2015-06-01 2016-05-31 3,3-дифторпиперидинкарбаматные гетероциклические соединения в качестве антагонистов nr2b nmda-рецептора

Country Status (17)

Country Link
US (4) US10584127B2 (enExample)
EP (1) EP3303323B1 (enExample)
JP (1) JP6876625B2 (enExample)
KR (1) KR102613179B1 (enExample)
CN (1) CN107849010B (enExample)
AR (1) AR104837A1 (enExample)
AU (1) AU2016270677B2 (enExample)
BR (1) BR112017025023B1 (enExample)
CA (1) CA2987606C (enExample)
DK (1) DK3303323T3 (enExample)
ES (1) ES2784398T3 (enExample)
IL (1) IL255937B (enExample)
MX (1) MX380424B (enExample)
RU (1) RU2735277C2 (enExample)
TW (1) TWI721987B (enExample)
WO (1) WO2016196513A1 (enExample)
ZA (1) ZA201708006B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017002775A (es) 2014-09-15 2017-08-10 Rugen Holdings (Cayman) Ltd Derivados de pirrolopirimidina como antagonistas del receptor de n-metil-d-aspartato (nmda), subunidad nr2b.
US10221182B2 (en) 2015-02-04 2019-03-05 Rugen Holdings (Cayman) Limited 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists
CA2987606C (en) 2015-06-01 2024-02-20 Rugen Holdings (Cayman) Limited 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists
CN106986874B (zh) * 2016-01-20 2019-09-24 西华大学 (1H-吡唑[3,4-d]嘧啶)-4-氨基衍生物及其作为IDO抑制剂在药物制备中的用途
WO2018098128A1 (en) 2016-11-22 2018-05-31 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
IL297333B2 (en) 2020-04-17 2025-09-01 Honeybrains Llc Preparations and methods for treating neuropsychiatric disorders
CN117159541B (zh) * 2023-09-20 2026-05-26 南华大学 Nat10拮抗剂在制备预防和/或治疗癫痫的药物中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108705A1 (en) * 2003-06-04 2004-12-16 Merck & Co., Inc. 3-fluoro-piperidines as nmda/nr2b antagonists
US20100105650A1 (en) * 2006-12-27 2010-04-29 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives
US20110280808A1 (en) * 2010-04-16 2011-11-17 Ac Immune, S.A. Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins
RU2499598C2 (ru) * 2008-03-27 2013-11-27 Евотек Интернациональ Гмбх Способы лечения нарушений с применением селективного антагониста nr2b-подтипа nmda рецепторов
US20140336185A1 (en) * 2011-05-31 2014-11-13 Receptos, Inc. Novel glp-1 receptor stabilizers and modulators

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3717867A1 (de) 1987-05-26 1988-12-15 Schiepe Stapelautomaten Gmbh Stapelvorrichtung
IL122649A (en) 1995-08-11 2001-08-26 Pfizer (1s, 2s) - 1- (4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol methanesulfonate trihydrate, its use in the preparation of medicaments and pharmaceutical compositions comprising same
GB9805977D0 (en) * 1998-03-19 1998-05-20 Silver Joshua D Improvements in variable focus optical devices
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
HU227197B1 (en) 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
MXPA03007621A (es) 2001-02-23 2003-12-04 Merck & Co Inc Antagonistas nr2b de n-metil-d-aspartato no arilheterociclicos n-sustituidos.
US7592360B2 (en) 2003-06-04 2009-09-22 Merck & Co., Inc. 3-fluoro-piperidines as NMDA/NR2B antagonists
WO2005102390A2 (en) 2004-04-22 2005-11-03 Pfizer Japan, Inc. Combinations comprising alpha-2-delta ligands and nmda receptor antagonists
US20070293515A1 (en) 2004-08-03 2007-12-20 Layton Mark E 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists
CA2591738A1 (en) * 2004-12-22 2006-06-29 Merck & Co., Inc. Process for making substituted piperidines
CA2603876A1 (en) 2005-04-19 2006-10-26 Merck & Co., Inc. N-alkyl-azacycloalkyl nmda/nr2b antagonists
WO2007061868A2 (en) 2005-11-17 2007-05-31 Trustees Of Tufts College Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors
EP2520567A3 (en) 2006-02-23 2012-12-12 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
CA2662702A1 (en) * 2006-09-07 2008-03-13 Merck & Co., Inc. Difluorinated piperidines for treatment of alzheimer's disease and related conditions
US20100010565A1 (en) * 2008-07-09 2010-01-14 Samuel Victor Lichtenstein Extended range wireless muscular and neural stimulation
WO2010015637A1 (en) 2008-08-06 2010-02-11 Novartis Ag New antiviral modified nucleosides
EP2519241A2 (en) 2009-12-28 2012-11-07 Afraxis, Inc. Methods for treating autism
US20130231348A1 (en) 2010-06-09 2013-09-05 Afraxis, Inc. 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS
WO2011159945A2 (en) 2010-06-16 2011-12-22 Afraxis, Inc. Methods for treating neurological conditions
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US20140005188A1 (en) 2011-03-11 2014-01-02 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
AU2013251079B2 (en) * 2012-04-20 2017-03-23 Ucb Pharma S.A. Methods for treating Parkinson's disease
EA029056B1 (ru) * 2012-12-11 2018-02-28 Такеда Фармасьютикал Компани Лимитед Гетероциклическое соединение
CN105308049A (zh) 2013-01-29 2016-02-03 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
JP2017500287A (ja) * 2013-11-06 2017-01-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｇｓｋ−３阻害剤として有用な置換ピリジン誘導体
US9221796B2 (en) * 2014-01-09 2015-12-29 Bristol-Myers Squibb Company Selective NR2B antagonists
BR112016025910A8 (pt) 2014-05-06 2021-07-13 Univ Northwestern uso de uma quantidade eficaz de glyx-13, uso de glyx-13 e um antagonista de nmdar e composição farmaceuticamente aceitável compreendendo os mesmos
US10030026B2 (en) 2014-06-04 2018-07-24 Rugen Holdings (Cayman) Limited Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists
MX2017002775A (es) 2014-09-15 2017-08-10 Rugen Holdings (Cayman) Ltd Derivados de pirrolopirimidina como antagonistas del receptor de n-metil-d-aspartato (nmda), subunidad nr2b.
US20180271869A1 (en) 2014-09-22 2018-09-27 Jie Liu Treatment of anxiety disorders and autism spectrum disorders
WO2016100349A2 (en) 2014-12-16 2016-06-23 Rugen Holdings (Cayman) Limited Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists
US10221182B2 (en) 2015-02-04 2019-03-05 Rugen Holdings (Cayman) Limited 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists
CA2987606C (en) 2015-06-01 2024-02-20 Rugen Holdings (Cayman) Limited 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists
WO2018098128A1 (en) 2016-11-22 2018-05-31 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108705A1 (en) * 2003-06-04 2004-12-16 Merck & Co., Inc. 3-fluoro-piperidines as nmda/nr2b antagonists
US20100105650A1 (en) * 2006-12-27 2010-04-29 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives
RU2499598C2 (ru) * 2008-03-27 2013-11-27 Евотек Интернациональ Гмбх Способы лечения нарушений с применением селективного антагониста nr2b-подтипа nmda рецепторов
US20110280808A1 (en) * 2010-04-16 2011-11-17 Ac Immune, S.A. Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins
US20140336185A1 (en) * 2011-05-31 2014-11-13 Receptos, Inc. Novel glp-1 receptor stabilizers and modulators

Also Published As

Publication number Publication date
US10294230B2 (en) 2019-05-21
ES2784398T3 (es) 2020-09-24
JP6876625B2 (ja) 2021-05-26
EP3303323B1 (en) 2020-01-08
KR102613179B1 (ko) 2023-12-14
DK3303323T3 (da) 2020-03-23
CN107849010A (zh) 2018-03-27
NZ737780A (en) 2024-04-26
US20220024937A1 (en) 2022-01-27
CA2987606C (en) 2024-02-20
US10584127B2 (en) 2020-03-10
US20200299300A1 (en) 2020-09-24
MX2017015370A (es) 2018-03-15
IL255937B (en) 2021-06-30
RU2017142005A3 (enExample) 2019-11-19
AU2016270677A1 (en) 2017-12-14
BR112017025023B1 (pt) 2024-01-30
KR20180032533A (ko) 2018-03-30
US20180346476A1 (en) 2018-12-06
AU2016270677B2 (en) 2020-11-12
ZA201708006B (en) 2021-07-28
TWI721987B (zh) 2021-03-21
JP2018522831A (ja) 2018-08-16
EP3303323A1 (en) 2018-04-11
RU2017142005A (ru) 2019-07-09
EP3303323A4 (en) 2019-01-02
US11136328B2 (en) 2021-10-05
WO2016196513A1 (en) 2016-12-08
MX380424B (es) 2025-03-12
HK1253023A1 (en) 2019-06-06
TW201710248A (zh) 2017-03-16
IL255937A (en) 2018-01-31
AR104837A1 (es) 2017-08-16
CN107849010B (zh) 2021-11-09
BR112017025023A2 (pt) 2018-08-07
CA2987606A1 (en) 2016-12-08
US20180170935A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
US11136328B2 (en) 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists
RU2621049C2 (ru) Модуляторы рецептора нмда и их применение
TWI473803B (zh) 作為阿伐７正向異位調節劑之嗎福啉基噻唑
CN106715435B (zh) 作为nr2b nmda受体拮抗剂的吡咯并嘧啶衍生物
JP2022516685A (ja) ホスファターゼ結合化合物およびそれらを使用する方法
US11752155B2 (en) Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
WO2016100349A2 (en) Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists
CN110719779B (zh) 包含非外消旋比例的(r)-地来西坦(1)和(s)-地来西坦(2)的协同组合物
US8530453B2 (en) Compounds and methods for the treatment of pain and other diseases
WO2025101588A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
WO2025101571A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-x l degraders
HK1253023B (en) 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists
JPWO2003078441A1 (ja) アミノメチル置換チアゾロベンゾイミダゾール誘導体
BR112017004868B1 (pt) Derivados de pirrolopirimidina como antagonistas do receptor nmda nr2b e composição farmacêutica que os compreende
HK40016465A (en) Synergistic compositions comprising (r)-dimiracetam (1) and (s)-dimiracetam (2) in a non-racemic ratio